A Phase 1/2 interventional study of Remigromig in Neovascular Age-related Macular Degeneration (NVAMD) and Diabetic Macular Edema (DME), sponsored by EyeBiotech Ltd.. Completed at 32 sites in 4 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by EyeBiotech Ltd. (part of Merck & Co., Inc) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 645 studies in Macular Degeneration with a site in United States — 84 open to participants now, 128 under way, 24 of them phase 3. Macular Degeneration · United States.
Among the 645 studies in Macular Degeneration with a site in United States, this one is the 312th largest by enrollment of the 491 interventional ones that give a count, is one of 24 that started in 2023, is one of 61 in phase 1/2, and was the 548th registered.
1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.
Browse Macular Degeneration studies →84 of the 645 studies in Macular Degeneration with a site in United States are open now. Recruiting first, the newest first:
Genentech, Inc. · Sites in United States
Ages 50+
Biojiva LLC · Sites in United States, Australia
Ages 55+
Sitala Bio LTD · Sites in United States, Argentina, Australia and 4 more countries
Ages 60+
Scott Raymond · Sites in United States
Ages 50–80
Astellas Institute for Regenerative Medicine · Sites in United States
Ages 6+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 165 Macular Degeneration studies recruiting now, 116 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
645 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 152 · Phase 2 216 · Phase 3 103 · Phase 4 27
First in 1992; this study’s year is marked. 24 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 33 is below the median of 56 across 985 interventional studies indexed under Macular Degeneration.
Median enrollment 55 across the 491 interventional studies, 100 across the 146 observational. Of the 464 that completed or were terminated, 183 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
375 of 645 have an industry lead sponsor. The 10 most frequent:
This study is registered under EyeBiotech Ltd., one of the names counted as Merck & Co., Inc. Under that name alone:
EyeBiotech Ltd. is the lead sponsor of 7 studies on the registry; 3 are open to participants now.
Merck & Co., Inc has 5 studies filed under Macular Degeneration — fewer than ten, so there is no comparison to draw.
36 of the studies in Macular Degeneration with a site in United States that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04704921Phase 3AbbViePivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD | 2026-12 |
| NCT06495918Phase 3Ocular Therapeutix, Inc.Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration | 2027-01-08 |
| NCT06864988Phase 34D Molecular Therapeutics4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration | 2027-06 |
| NCT05904028Phase 3Jaeb Center for Health ResearchHome OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD | 2027-07-30 |
| NCT07614776Phase 3AmgenA Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration | 2027-07-31 |
Add all 36 to your calendar (.ics) → With an account.
Among the 645 studies in Macular Degeneration with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
EYE103-101 is a 2-part study assessing safety and preliminary efficacy of remigromig (EYE103) in patients with diabetic macular edema (DME) given as monotherapy or neovascular macular degeneration (NVAMD) given in combination with anti-VEGF.
In the first part, termed the multiple ascending dose (MAD) portion of study, the safety of remigromig will be assessed at escalating doses. Approximately 12 participants will be entered in this part of the study.
In the second part of the study, called the dose finding part two doses of remigromig will be selected and their effectiveness will be compared. Approximately 80 participants will be entered in this part of the study.
EYE103-101 is a 2-part study assessing safety and preliminary efficacy of remigromig in patients with diabetic macular edema (DME) given as monotherapy or neovascular macular degeneration (NVAMD) given in combination with anti-VEGF.
In the first part, termed the multiple ascending dose (MAD) portion of study, the safety of remigromig will be assessed at escalating doses. Approximately 12 participants will be entered in this part of the study.
In the second part of the study, called the dose finding part two doses of remigromig will be selected and their effectiveness will be compared. Approximately 80 participants will be entered in this part of the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part 1 MAD Portion Dose 1 - Low Dose
Drug: Remigromig
Part 1 MAD Portion Dose 2 - Low-Mid Dose
Drug: Remigromig
Part 1 MAD Portion Dose 3 - Mid-High Dose
Drug: Remigromig
Part 1 MAD Portion Dose 4 - High Dose
Drug: Remigromig
Part 2 Naïve DME monotherapy Medium Dose
Drug: Remigromig
Part 2 Naïve DME monotherapy High Dose
Drug: Remigromig
Part 2 Naïve NVAMD combination therapy Medium Dose
Drug: Remigromig
Part 2 Naïve NVAMD combination therapy High Dose
Drug: Remigromig
Part 2 Experienced NVAMD combination therapy Medium Dose
Drug: Remigromig
Part 2 Experienced NVAMD combination therapy High Dose
Drug: Remigromig
Remigromig is a humanized antibody formulated for IVT administration
Also known as: EYE103
Number of Participants Who Experienced a Dose-limiting Toxicity (DLT)
Systemic DLTs are defined as a Grade III (severe), IV (life threatening) or V (death related to adverse event) toxicities as defined in the National Cancer Institute (NCI) Common Toxicity Criteria, or any significant severe toxicity deemed related to study drug by the principal investigator. Ocular DLTs are defined as: loss of 4 or more lines of visual acuity, clinically significant inflammation, increase of intra-ocular pressure (IOP) from baseline of \> or =15 mmHg, accelerated formation of cataract, other severe ocular abnormalities not usually seen in subjects with the condition under study, or significant retinal or choroidal vascular abnormalities seen on fluorescein angiogram deemed related to study drug by the investigator.
Time frame: Up to approximately 12 weeks
Number of Participants Who Experienced an Adverse Event (AE)
An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Therefore, an AE can be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Time frame: Up to approximately 12 weeks
Number of Participants Who Experienced a Serious Adverse Event (SAE)
An SAE is defined as any adverse experience occurring at any dose that results in any of the following outcomes: Results in death; Is life threatening (immediate risk of death); results in persistent or significant disability/incapacity; requires participant hospitalization or prolongs participant hospitalization; or results in a congenital anomaly/birth defect in a neonate/infant
Time frame: Up to approximately 24 weeks
Number of Participants Who Experienced Clinically Meaningful Changes in Laboratory Assessments
Clinical laboratory tests, including overnight fasting serum chemistry, lipid panel, hematology, and coagulation panel were collected at baseline and at week 12 study visit. Any laboratory test result considered by the investigator to be clinically significant was considered to be an AE. Clinically significant abnormal values were followed up until repeat test results return to normal, stabilize, or are no longer clinically significant.
Time frame: Baseline and Week 12
Mean Change From Baseline in Best-Corrected Visual Acuity (BCVA) to Week 12 in the Study Eye - DME Participants
Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. Mean change in ETDRS letters from baseline to week 12 is presented.
Time frame: Baseline and Week 12
Mean Change From Baseline in BCVA to Week 12 in the Study Eye -NVAMD Participants
Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. Mean change in ETDRS letters from baseline to week 12 is presented.
Time frame: Baseline and Week 12
Number of Participants With ETDRS BCVA Response- Treatment-Naive DME Participants
Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The number of participants who gained 15 or more letters as measured by ETDRS from baseline in the study eye is presented.
Time frame: Baseline and Week 12
Number of Participants With ETDRS BCVA Response- Treatment-Naive NVAMD Participants
Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The number of participants who gained 15 or more letters as measured by ETDRS from baseline in the study eye is presented.
Time frame: Baseline and Week 12
Mean Change in Retinal Central Subfield Thickness (CST) From Baseline in the Study Eye on Spectral Domain Optical Coherence Tomography (SDOCT): Treatment-naive DME Participants
SDOCT machines and technicians were certified at each study site by the independent reading center (IRC) prior to study start. Images were sent to the IRC for assessment. A negative change (decrease) in retinal CST from baseline indicates a decrease in retinal thickness or swelling and is considered a better outcome than no change or an increase in CST. The mean change at 12 weeks in the study eye for retinal CST from baseline is presented.
Time frame: Baseline and 12 weeks
Mean Change in Retinal CST From Baseline in the Study Eye on SDOCT: Treatment-naive NVAMD Participants
SDOCT machines and technicians were certified at each study site by the independent reading center (IRC) prior to study start. Images were sent to the IRC for assessment. A negative change (decrease) in retinal CST from baseline indicates a decrease in retinal thickness or swelling and is considered a better outcome than no change or an increase in CST. The mean change at 12 weeks in the study eye for retinal CST from baseline is presented.
Time frame: Baseline and 12 weeks
Number of Participants With Loss of Vision From Baseline by 15 or More Letters at Week 12-Treatment Naive DME Participants
Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The number of participants who lost 15 or more letters as measured by ETDRS from baseline in the study eye is presented.
Time frame: Baseline and Week 12
Number of Participants With Loss of Vision From Baseline by 15 or More Letters at Week 12-Treatment Naive NVAMD Participants
Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The number of participants who lost 15 or more letters as measured by ETDRS from baseline in the study eye is presented.
Time frame: Baseline and Week 12
Percent Change in Excess Retinal Fluid From Baseline at Week 12: Treatment-naive DME Participants
Retinal fluid in the study eye was measured by central subfield thickness (CST) as evaluated on SDOCT. SDOCT machines and technicians were certified at each study site by the independent reading center (IRC) prior to study start. Images were sent to the IRC for assessment. This outcome measure evaluates the relative change in excess CST above \> 300 um from baseline to Week 12, expressed as a percentage of the baseline value. The percent change from baseline in CST in the study eye is calculated as follows: (Excess CST Baseline-Excess CST Week 12/Excess CST Baseline) \*100. Positive values represent a percent reduction in excess retinal fluid (clinical improvement), and negative values represent a percent increase in excess retinal fluid (clinical worsening).
Time frame: Baseline and Week 12
Percent Change in Excess Retinal Fluid From Baseline at Week 12: Treatment-naive NVAMD Participants
Retinal fluid in the study eye was measured by central subfield thickness (CST) as evaluated on SDOCT. SDOCT machines and technicians were certified at each study site by the independent reading center (IRC) prior to study start. Images were sent to the IRC for assessment. This outcome measure evaluates the relative change in excess CST above \> 300 um from baseline to Week 12, expressed as a percentage of the baseline value. The percent change from baseline in CST in the study eye is calculated as follows: (Excess CST Baseline-Excess CST Week 12/Excess CST Baseline) \*100. Positive values represent a percent reduction in excess retinal fluid (clinical improvement), and negative values represent a percent increase in excess retinal fluid (clinical worsening).
Time frame: Baseline and Week 12
This study consisted of two parts. Part 1, the multiple ascending dose (MAD) phase, evaluated escalating doses of remigromig (EYE103) in participants with treatment-naive diabetic macular edema (DME) and in participants with neovascular age-related macular degeneration (NVAMD). Part 2 compared two selected remigromig doses and was planned to enroll participants with DME and NVAMD (both treatment-naïve and previously treated); however, no participants with NVAMD were enrolled.
| Milestone | Part 1: Remigromig 0.05 mg | Part 1: Remigromig 0.15 mg | Part 1: Remigromig 0.48 mg | Part1: Remigromig 0.8 mg | Part 2: Remigromig Diabetic Macular Edema (DME) 0.48 mg | Part 2: Remigromig DME 0.8 mg | Part 2: Remigromig Neovascular Age-Related Macular Degeneration (NVAMD) 0.48 mg | Part 2: Remigromig NVAMD 0.8 mg | Part 2: Remigromig Experienced NVAMD 0.48 mg | Part 2: Remigromig Experienced NVAMD 0.8 mg |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 3 | 3 | 3 | 11 | 10 | 0 | 0 | 0 | 0 |
| Received additional remigromig injections | 0 | 0 | 2 | 1 | 3 | 3 | 0 | 0 | 0 | 0 |
| Participants with dme | 0 | 3 | 2 | 2 | 11 | 10 | 0 | 0 | 0 | 0 |
| Participants with nvamd | 3 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 3 | 3 | 3 | 3 | 10 | 9 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The number of participants who gained 15 or more letters as measured by ETDRS from baseline in the study eye is presented.
| Participants | Part 1: Remigromig 0.05 mg | Part 1: Remigromig 0.15 mg | Part 1: Remigromig 0.48 mg | Part 1: Remigromig 0.8 mg | Part 2: Remigromig Diabetic Macular Edema (DME) 0.48 mg | Part 2: Remigromig DME 0.8 mg |
|---|---|---|---|---|---|---|
| Number of Participants With ETDRS BCVA Response- Treatment-Naive DME Participants | — | 0 | 1 | 0 | 4 | 2 |
Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The number of participants who gained 15 or more letters as measured by ETDRS from baseline in the study eye is presented.
| Participants | Part 1: Remigromig 0.05 mg | Part 1: Remigromig 0.15 mg | Part 1: Remigromig 0.48 mg | Part 1: Remigromig 0.8 mg | Part 2: Remigromig Diabetic Macular Edema (DME) 0.48 mg | Part 2: Remigromig DME 0.8 mg |
|---|---|---|---|---|---|---|
| Number of Participants With ETDRS BCVA Response- Treatment-Naive NVAMD Participants | 0 | — | 0 | 0 | — | — |
SDOCT machines and technicians were certified at each study site by the independent reading center (IRC) prior to study start. Images were sent to the IRC for assessment. A negative change (decrease) in retinal CST from baseline indicates a decrease in retinal thickness or swelling and is considered a better outcome than no change or an increase in CST. The mean change at 12 weeks in the study eye for retinal CST from baseline is presented.
| μm | Part 1: Remigromig 0.05 mg | Part 1: Remigromig 0.15 mg | Part 1: Remigromig 0.48 mg | Part 1: Remigromig 0.8 mg | Part 2: Remigromig Diabetic Macular Edema (DME) 0.48 mg | Part 2: Remigromig DME 0.8 mg |
|---|---|---|---|---|---|---|
| Mean Change in Retinal Central Subfield Thickness (CST) From Baseline in the Study Eye on Spectral Domain Optical Coherence Tomography (SDOCT): Treatment-naive DME Participants | — | -120 ± 97.51 | -251 ± 39.60 | -162 ± 43.13 | -131 ± 68.13 | -144 ± 151.28 |
SDOCT machines and technicians were certified at each study site by the independent reading center (IRC) prior to study start. Images were sent to the IRC for assessment. A negative change (decrease) in retinal CST from baseline indicates a decrease in retinal thickness or swelling and is considered a better outcome than no change or an increase in CST. The mean change at 12 weeks in the study eye for retinal CST from baseline is presented.
| μm | Part 1: Remigromig 0.05 mg | Part 1: Remigromig 0.15 mg | Part 1: Remigromig 0.48 mg | Part 1: Remigromig 0.8 mg | Part 2: Remigromig Diabetic Macular Edema (DME) 0.48 mg | Part 2: Remigromig DME 0.8 mg |
|---|---|---|---|---|---|---|
| Mean Change in Retinal CST From Baseline in the Study Eye on SDOCT: Treatment-naive NVAMD Participants | -277 ± 176.67 | — | -149 ± NA | -363 ± NA | — | — |
Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The number of participants who lost 15 or more letters as measured by ETDRS from baseline in the study eye is presented.
| Participants | Part 1: Remigromig 0.05 mg | Part 1: Remigromig 0.15 mg | Part 1: Remigromig 0.48 mg | Part 1: Remigromig 0.8 mg | Part 2: Remigromig Diabetic Macular Edema (DME) 0.48 mg | Part 2: Remigromig DME 0.8 mg |
|---|---|---|---|---|---|---|
| Number of Participants With Loss of Vision From Baseline by 15 or More Letters at Week 12-Treatment Naive DME Participants | 0 | 0 | 0 | 00 | 0 | 0 |
Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The number of participants who lost 15 or more letters as measured by ETDRS from baseline in the study eye is presented.
| Participants | Part 1: Remigromig 0.05 mg | Part 1: Remigromig 0.15 mg | Part 1: Remigromig 0.48 mg | Part 1: Remigromig 0.8 mg | Part 2: Remigromig Diabetic Macular Edema (DME) 0.48 mg | Part 2: Remigromig DME 0.8 mg |
|---|---|---|---|---|---|---|
| Number of Participants With Loss of Vision From Baseline by 15 or More Letters at Week 12-Treatment Naive NVAMD Participants | 0 | — | 0 | 0 | — | — |
Retinal fluid in the study eye was measured by central subfield thickness (CST) as evaluated on SDOCT. SDOCT machines and technicians were certified at each study site by the independent reading center (IRC) prior to study start. Images were sent to the IRC for assessment. This outcome measure evaluates the relative change in excess CST above \> 300 um from baseline to Week 12, expressed as a percentage of the baseline value. The percent change from baseline in CST in the study eye is calculated as follows: (Excess CST Baseline-Excess CST Week 12/Excess CST Baseline) \*100. Positive values represent a percent reduction in excess retinal fluid (clinical improvement), and negative values represent a percent increase in excess retinal fluid (clinical worsening).
| Percentage change from baseline | Part 1: Remigromig 0.05 mg | Part 1: Remigromig 0.15 mg | Part 1: Remigromig 0.48 mg | Part 1: Remigromig 0.8 mg | Part 2: Remigromig Diabetic Macular Edema (DME) 0.48 mg | Part 2: Remigromig DME 0.8 mg |
|---|---|---|---|---|---|---|
| Percent Change in Excess Retinal Fluid From Baseline at Week 12: Treatment-naive DME Participants | — | 77.19 ± 51.404 | 92.08 ± 8.350 | 60.66 ± 34.892 | 81.84 ± 12.364 | 81.00 ± 39.177 |
Retinal fluid in the study eye was measured by central subfield thickness (CST) as evaluated on SDOCT. SDOCT machines and technicians were certified at each study site by the independent reading center (IRC) prior to study start. Images were sent to the IRC for assessment. This outcome measure evaluates the relative change in excess CST above \> 300 um from baseline to Week 12, expressed as a percentage of the baseline value. The percent change from baseline in CST in the study eye is calculated as follows: (Excess CST Baseline-Excess CST Week 12/Excess CST Baseline) \*100. Positive values represent a percent reduction in excess retinal fluid (clinical improvement), and negative values represent a percent increase in excess retinal fluid (clinical worsening).
| Percentage change from baseline | Part 1: Remigromig 0.05 mg | Part 1: Remigromig 0.15 mg | Part 1: Remigromig 0.48 mg | Part 1: Remigromig 0.8 mg | Part 2: Remigromig Diabetic Macular Edema (DME) 0.48 mg | Part 2: Remigromig DME 0.8 mg |
|---|---|---|---|---|---|---|
| Percent Change in Excess Retinal Fluid From Baseline at Week 12: Treatment-naive NVAMD Participants | 187.41 ± 121.251 | — | 133.04 ± NA | 109.67 ± NA | — | — |
Systemic DLTs are defined as a Grade III (severe), IV (life threatening) or V (death related to adverse event) toxicities as defined in the National Cancer Institute (NCI) Common Toxicity Criteria, or any significant severe toxicity deemed related to study drug by the principal investigator. Ocular DLTs are defined as: loss of 4 or more lines of visual acuity, clinically significant inflammation, increase of intra-ocular pressure (IOP) from baseline of \> or =15 mmHg, accelerated formation of cataract, other severe ocular abnormalities not usually seen in subjects with the condition under study, or significant retinal or choroidal vascular abnormalities seen on fluorescein angiogram deemed related to study drug by the investigator.
| Participants | Part 1: Remigromig 0.05 mg | Part 1: Remigromig 0.15 mg | Part 1: Remigromig 0.48 mg | Part 1: Remigromig 0.8 mg | Part 2: Remigromig Diabetic Macular Edema (DME) 0.48 mg | Part 2: Remigromig DME 0.8 mg |
|---|---|---|---|---|---|---|
| Number of Participants Who Experienced a Dose-limiting Toxicity (DLT) | 0 | 0 | 0 | 0 | 0 | 0 |
An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Therefore, an AE can be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
| Participants | Part 1: Remigromig 0.05 mg | Part 1: Remigromig 0.15 mg | Part 1: Remigromig 0.48 mg | Part 1: Remigromig 0.8 mg | Part 2: Remigromig Diabetic Macular Edema (DME) 0.48 mg | Part 2: Remigromig DME 0.8 mg |
|---|---|---|---|---|---|---|
| Number of Participants Who Experienced an Adverse Event (AE) | 2 | 1 | 2 | 3 | 5 | 4 |
An SAE is defined as any adverse experience occurring at any dose that results in any of the following outcomes: Results in death; Is life threatening (immediate risk of death); results in persistent or significant disability/incapacity; requires participant hospitalization or prolongs participant hospitalization; or results in a congenital anomaly/birth defect in a neonate/infant
| Participants | Part 1: Remigromig 0.05 mg | Part 1: Remigromig 0.15 mg | Part 1: Remigromig 0.48 mg | Part 1: Remigromig 0.8 mg | Part 2: Remigromig Diabetic Macular Edema (DME) 0.48 mg | Part 2: Remigromig DME 0.8 mg |
|---|---|---|---|---|---|---|
| Number of Participants Who Experienced a Serious Adverse Event (SAE) | 0 | 0 | 0 | 0 | 0 | 1 |
Clinical laboratory tests, including overnight fasting serum chemistry, lipid panel, hematology, and coagulation panel were collected at baseline and at week 12 study visit. Any laboratory test result considered by the investigator to be clinically significant was considered to be an AE. Clinically significant abnormal values were followed up until repeat test results return to normal, stabilize, or are no longer clinically significant.
| Participants | Part 1: Remigromig 0.05 mg | Part 1: Remigromig 0.15 mg | Part 1: Remigromig 0.48 mg | Part 1: Remigromig 0.8 mg | Part 2: Remigromig Diabetic Macular Edema (DME) 0.48 mg | Part 2: Remigromig DME 0.8 mg |
|---|---|---|---|---|---|---|
| Number of Participants Who Experienced Clinically Meaningful Changes in Laboratory Assessments | 0 | 0 | 0 | 0 | 0 | 0 |
Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. Mean change in ETDRS letters from baseline to week 12 is presented.
| Change in ETDRS letters | Part 1: Remigromig 0.05 mg | Part 1: Remigromig 0.15 mg | Part 1: Remigromig 0.48 mg | Part 1: Remigromig 0.8 mg | Part 2: Remigromig Diabetic Macular Edema (DME) 0.48 mg | Part 2: Remigromig DME 0.8 mg |
|---|---|---|---|---|---|---|
| Mean Change From Baseline in Best-Corrected Visual Acuity (BCVA) to Week 12 in the Study Eye - DME Participants | — | 5.3 ± 1.53 | 14.5 ± 2.12 | 10.0 ± 5.6 | 14.1 ± 6.74 | 9.9 ± 8.42 |
Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. Mean change in ETDRS letters from baseline to week 12 is presented.
| Change in ETDRS letters | Part 1: Remigromig 0.05 mg | Part 1: Remigromig 0.15 mg | Part 1: Remigromig 0.48 mg | Part 1: Remigromig 0.8 mg | Part 2: Remigromig Diabetic Macular Edema (DME) 0.48 mg | Part 2: Remigromig DME 0.8 mg |
|---|---|---|---|---|---|---|
| Mean Change From Baseline in BCVA to Week 12 in the Study Eye -NVAMD Participants | 6.7 ± 2.52 | — | 14.0 ± NA | 0.0 ± NA | — | — |
Collected over Up to approximately 24 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Remigromig 0.05 mg | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| Part 1: Remigromig 0.15 mg | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) |
| Part 1: Remigromig 0.48 mg | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| Part 1: Remigromig 0.8 mg | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Part 2: Remigromig Diabetic Macular Edema (DME) 0.48 mg | 0/11 (0%) | 0/11 (0%) | 5/11 (45.5%) |
| Part 2: Remigromig DME 0.8 mg | 0/10 (0%) | 1/10 (10%) | 4/10 (40%) |
| Part 2: Remigromig Neovascular Age-Related Macular Degeneration (NVAMD) 0.48 mg | — | — | — |
| Part 2: Remigromig NVAMD 0.8 mg | — | — | — |
| Part 2: Remigromig Experienced NVAMD 0.48 mg | — | — | — |
| Part 2: Remigromig Experienced NVAMD 0.8 mg | — | — | — |
| Event | Part 1: Remigromig 0.05 mg | Part 1: Remigromig 0.15 mg | Part 1: Remigromig 0.48 mg | Part 1: Remigromig 0.8 mg | Part 2: Remigromig Diabetic Macular Edema (DME) 0.48 mg | Part 2: Remigromig DME 0.8 mg | Part 2: Remigromig Neovascular Age-Related Macular Degeneration (NVAMD) 0.48 mg | Part 2: Remigromig NVAMD 0.8 mg | Part 2: Remigromig Experienced NVAMD 0.48 mg | Part 2: Remigromig Experienced NVAMD 0.8 mg |
|---|---|---|---|---|---|---|---|---|---|---|
| OsteomyelitisInfections and infestations | 0/3 | 0/3 | 0/3 | 0/3 | 0/11 | 1/10 | — | — | — | — |
| Staphylococcal bacteraemiaInfections and infestations | 0/3 | 0/3 | 0/3 | 0/3 | 0/11 | 1/10 | — | — | — | — |
| Event | Part 1: Remigromig 0.05 mg | Part 1: Remigromig 0.15 mg | Part 1: Remigromig 0.48 mg | Part 1: Remigromig 0.8 mg | Part 2: Remigromig Diabetic Macular Edema (DME) 0.48 mg | Part 2: Remigromig DME 0.8 mg | Part 2: Remigromig Neovascular Age-Related Macular Degeneration (NVAMD) 0.48 mg | Part 2: Remigromig NVAMD 0.8 mg | Part 2: Remigromig Experienced NVAMD 0.48 mg | Part 2: Remigromig Experienced NVAMD 0.8 mg |
|---|---|---|---|---|---|---|---|---|---|---|
| AsthenopiaEye disorders | 1/3 | 0/3 | 0/3 | 0/3 | 0/11 | 0/10 | — | — | — | — |
| CataractEye disorders | 0/3 | 0/3 | 0/3 | 1/3 | 0/11 | 0/10 | — | — | — | — |
| Conjunctival haemorrhageEye disorders | 0/3 | 1/3 | 0/3 | 0/3 | 1/11 | 0/10 | — | — | — | — |
| Diabetic retinopathyEye disorders | 0/3 | 0/3 | 1/3 | 0/3 | 0/11 | 0/10 | — | — | — | — |
| Eye PainEye disorders | 1/3 | 0/3 | 0/3 | 0/3 | 0/11 | 0/10 | — | — | — | — |
| Ocular hypertensionEye disorders | 0/3 | 1/3 | 0/3 | 0/3 | 0/11 | 0/10 | — | — | — | — |
| Retinal haemorrhageEye disorders | 0/3 | 0/3 | 0/3 | 1/3 | 0/11 | 0/10 | — | — | — | — |
| Vision blurredEye disorders | 1/3 | 0/3 | 0/3 | 0/3 | 0/11 | 0/10 | — | — | — | — |
| Vitreous floatersEye disorders | 1/3 | 0/3 | 0/3 | 0/3 | 0/11 | 0/10 | — | — | — | — |
| Sensation of foreign bodyGeneral disorders | 1/3 | 0/3 | 0/3 | 0/3 | 0/11 | 0/10 | — | — | — | — |
Two cohorts of treatment-naïve NVAMD participants, and 2 cohorts of treatment-experienced participants were planned to be included in Part 2 of this study, however, no participants with NVAMD were enrolled in part 2 of this study
| Age, Continuous(Years) | Part 1: Remigromig 0.05 mg | Part 1: Remigromig 0.15 mg | Part 1: Remigromig 0.48 mg | Part1: Remigromig 0.8 mg | Part 2: Remigromig Diabetic Macular Edema (DME) 0.48 mg | Part 2: Remigromig DME 0.8 mg | Part 2: Remigromig Neovascular Age-Related Macular Degeneration (NVAMD) 0.48 mg | Part 2: Remigromig NVAMD 0.8 mg | Part 2: Remigromig Experienced NVAMD 0.48 mg | Part 2: Remigromig Experienced NVAMD 0.8 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 79.0 ± 15.13 | 66.3 ± 7.37 | 66.3 ± 15.53 | 60.0 ± 12.29 | 62.0 ± 6.29 | 58.1 ± 6.79 | — | — | — | — | 63.0 ± 10.12 |
| Sex: Female, Male(Participants) | Part 1: Remigromig 0.05 mg | Part 1: Remigromig 0.15 mg | Part 1: Remigromig 0.48 mg | Part1: Remigromig 0.8 mg | Part 2: Remigromig Diabetic Macular Edema (DME) 0.48 mg | Part 2: Remigromig DME 0.8 mg | Part 2: Remigromig Neovascular Age-Related Macular Degeneration (NVAMD) 0.48 mg | Part 2: Remigromig NVAMD 0.8 mg | Part 2: Remigromig Experienced NVAMD 0.48 mg | Part 2: Remigromig Experienced NVAMD 0.8 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 3 | 2 | 2 | 0 | 5 | 2 | 0 | 0 | 0 | 0 | 14 |
| Male | 0 | 1 | 1 | 3 | 6 | 8 | 0 | 0 | 0 | 0 | 19 |
| Race and Ethnicity Not Collected(Participants) | Part 1: Remigromig 0.05 mg | Part 1: Remigromig 0.15 mg | Part 1: Remigromig 0.48 mg | Part1: Remigromig 0.8 mg | Part 2: Remigromig Diabetic Macular Edema (DME) 0.48 mg | Part 2: Remigromig DME 0.8 mg | Part 2: Remigromig Neovascular Age-Related Macular Degeneration (NVAMD) 0.48 mg | Part 2: Remigromig NVAMD 0.8 mg | Part 2: Remigromig Experienced NVAMD 0.48 mg | Part 2: Remigromig Experienced NVAMD 0.8 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Count of participants | — | — | — | — | — | — | — | — | — | — | 0 |
| Best-corrected Visual Acuity (BCVA) at Baseline(ETDRS Letters) | Part 1: Remigromig 0.05 mg | Part 1: Remigromig 0.15 mg | Part 1: Remigromig 0.48 mg | Part1: Remigromig 0.8 mg | Part 2: Remigromig Diabetic Macular Edema (DME) 0.48 mg | Part 2: Remigromig DME 0.8 mg | Part 2: Remigromig Neovascular Age-Related Macular Degeneration (NVAMD) 0.48 mg | Part 2: Remigromig NVAMD 0.8 mg | Part 2: Remigromig Experienced NVAMD 0.48 mg | Part 2: Remigromig Experienced NVAMD 0.8 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 50.7 ± 14.01 | 53.7 ± 9.71 | 56.3 ± 8.50 | 48.7 ± 11.15 | 61.4 ± 5.08 | 61.5 ± 6.60 | — | — | — | — | 58.1 ± 8.59 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2023 to primary completion in Aug 2024, 14 months.
Results were first posted in Sep 2026, 2 years 1 month after primary completion. A results delay was requested in Aug 2024.
Of 52 phase 1/2 interventional studies under Macular Degeneration, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 65. This study's 14 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Remigromig